ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ALMR?
Source: moomoo
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMR
Wall Street analysts forecast ALMR stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.660
Low
Averages
High
Current: 23.660
Low
Averages
High
No data
About ALMR
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALAMAR BIOSCIENCES REPORTS Q1 EPS OF $-1.74
- Earnings Per Share (EPS): The reported EPS for Q1 is $-1.74.
- Company Name: The summary pertains to Alamar Biosciences.
See More
ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
See More
Alamar Biosciences Q1 Financial Results
- Financial Performance: Alamar Biosciences reported a Q1 GAAP EPS of -$1.74, yet achieved revenues of $26 million, reflecting a robust 98.5% year-over-year growth that underscores the company's strong market potential.
- IPO Dynamics: The firm is experiencing increased cash burn leading up to its IPO, indicating a significant investment in expansion and R&D, which may exert short-term pressure on its financial health.
- Stock Price Movement: Following its IPO, Alamar Biosciences' stock surged by 40%, signaling positive market sentiment regarding its business model and future growth prospects, potentially attracting more investor interest.
- Pricing Strategy: The company successfully priced its upsized IPO at $17 per share, demonstrating market confidence in its valuation while providing necessary capital for future development.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
April IPO Market Rebounds with $7.3 Billion Raised
- Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
- Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
- Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
- Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
See More
Alamar Biosciences Successfully Lists on NASDAQ
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an issue price of $17 per share and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to invest in subsequent Series B and C rounds, holding approximately 19.2% of the company before its IPO, demonstrating strong confidence in its long-term growth potential.
- Technological Innovation: Alamar's self-developed NULISA™ technology overcomes design limitations of existing proteomics tools, delivering ultra-high sensitivity and specificity in protein detection, filling critical gaps left by other methods and paving the way for the future of early disease screening and precision diagnostics.
- Market Penetration: By the end of 2025, Alamar's ARGO™ HT fully automated high-throughput system had installed over 100 units across 25 countries, serving more than 300 customers, driving rapid growth in product market penetration and further solidifying its leadership position in the global market.
See More
ALAMAR BIOSCIENCES REPORTS Q1 EPS OF $-1.74
- Earnings Per Share (EPS): The reported EPS for Q1 is $-1.74.
- Company Name: The summary pertains to Alamar Biosciences.
See More
ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
See More
Alamar Biosciences Q1 Financial Results
- Financial Performance: Alamar Biosciences reported a Q1 GAAP EPS of -$1.74, yet achieved revenues of $26 million, reflecting a robust 98.5% year-over-year growth that underscores the company's strong market potential.
- IPO Dynamics: The firm is experiencing increased cash burn leading up to its IPO, indicating a significant investment in expansion and R&D, which may exert short-term pressure on its financial health.
- Stock Price Movement: Following its IPO, Alamar Biosciences' stock surged by 40%, signaling positive market sentiment regarding its business model and future growth prospects, potentially attracting more investor interest.
- Pricing Strategy: The company successfully priced its upsized IPO at $17 per share, demonstrating market confidence in its valuation while providing necessary capital for future development.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
April IPO Market Rebounds with $7.3 Billion Raised
- Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
- Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
- Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
- Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
See More
Alamar Biosciences Successfully Lists on NASDAQ
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an issue price of $17 per share and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to invest in subsequent Series B and C rounds, holding approximately 19.2% of the company before its IPO, demonstrating strong confidence in its long-term growth potential.
- Technological Innovation: Alamar's self-developed NULISA™ technology overcomes design limitations of existing proteomics tools, delivering ultra-high sensitivity and specificity in protein detection, filling critical gaps left by other methods and paving the way for the future of early disease screening and precision diagnostics.
- Market Penetration: By the end of 2025, Alamar's ARGO™ HT fully automated high-throughput system had installed over 100 units across 25 countries, serving more than 300 customers, driving rapid growth in product market penetration and further solidifying its leadership position in the global market.
See More
